Inadequate response to antiplatelet therapy in patients with peripheral artery disease: a prospective cohort study
CONCLUSIONS: Patients suffering from cardiovascular events and mortality were characterized by prior cardiovascular events as compared to patients who did not experience any events. Antiplatelet therapy was not optimally protective despite high medication adherence, and HTPR was independently associated with the occurrence of events. More research is needed on alternative treatment strategies such as dual antiplatelet therapy or combinations with anticoagulant drugs.TRIAL REGISTRATION: The Medical Ethics Committee (METC) of the MUMC+ approved the study (NL63235.068.17) and the study was registered in the Netherlands Trial Register ( NTR7250 ).PMID:36627677 | DOI:10.1186/s12959-022-00445-4
Source: Atherosclerosis - Category: Cardiology Authors: B M M Kremers J H C Daemen H Ten Cate H M H Spronk B M E Mees A J Ten Cate-Hoek Source Type: research
More News: Aspirin | Cardiology | Cardiovascular | Clopidogrel | Heart | Heart Attack | Intermittent Claudication | Ischemic Stroke | Medical Ethics | Netherlands Health | Peripheral Vascular Disease (PVD) | Plavix | Stroke | Study